Amid the rush for a SARS-CoV-2 vaccine to deal with the COVID-19 pandemic, a robust risk assessment must be conducted, and mitigation strategies applied.
Rajika Jindani
Advertisement
Rajika Jindani is a medical resident at University of Miami.
Articles by Rajika Jindani
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on BioPharm International
1
Alvotech, Advanz Submit First Eylea 8 mg Biosimilar Bid
2
Lilly's Mirikizumab (Omvoh) Hits New IBD Remission Goals
3
Shift to In Vivo CAR T Will Reshape Facility Design, Says Arcadis’ Emily Heffernan
4
FDA Accepts BLA for Formycon and Zydus’ FYB206, the First Publicly Announced Keytruda Biosimilar Under Review
5